Replies to post #52385 on CV Sciences Inc (CVSI)

[jefra1965]

900K spent in new equipment last year during Q3 and Q4 last year already. Not much in Q1'19 ($54K).

I don't see much spending left. Maybe another $500k at the most but VSI is cash flow positive.

My estimate using $17.5M as revenue for the upcoming Q report is $1.5M Net Income.

And that's keeping $1.4M in R&D. Not bad considering last Q report. I expect the next Q report to bring back stability in the growth trends and show profitability and positive free cash flow. I'll be happy with that.

You never hear J Dowling bragging or pumping anything so if he says there is growth currently and ahead, then there is GROWTH happening.

“Our recently announced U.S. hemp sourcing initiative combined with this facility and capacity expansion positions CV Sciences for continued rapid domestic growth, while ensuring we are well-positioned to capitalize on the international opportunities we are currently exploring,” said Joseph Dowling, Chief Executive Officer. “The distribution of PlusCBDTM Oil products into national retailers in the Food, Drug and Mass (FDM)channel is growing significantly, yet we are still in the early stages of growth. Despite more than doubling the number of stores carrying our industry leading products to 4,591 stores in the first six months of this year, we see a significant runway for additional growth, including increasing our domestic and international store count, as well as broadening product SKUs with our retail partners.”
On July 10, 2019, CV Sciences announced the commencement of its domestic hemp sourcing initiative, including a commitment to more than 500 acres of U.S.-based hemp production for 2019. This new supply of U.S. produced hemp-based CBD will be extracted through CV Sciences’ domestic supply chain partners and refined at the Company’s San Diego production facilities, broadening the Company’s global supply chain and raw material supply while reducing transportation and logistics costs.
Dowling continued, “CV Sciences is the first hemp CBD company to achieve self-affirmed Generally Recognized as Safe (GRAS) status in accordance with stringent U.S. Food and Drug Administration safety guidelines. Our relentless commitment to regulatory leadership as well as product safety, quality and efficacy through scientific evidence has established confidence and trust with retailers and consumers. Expanding our GRAS raw material supply capability builds on our strong foundation to make PlusCBDTM Oil products available to more consumers around the globe.”